Lung cancer, which has a low survival rate, is a leading cause of cancer-associated mortality
worldwide. Smoking and air pollution are the major causes of lung cancer; however …

Severe adverse systemic drug events occur commonly as a result of treatment of cancer
patients. Nephrotoxicity of chemotherapeutic agents remains a significant complication …

Medullary thyroid cancer (MTC) represents 3% of all clinical thyroid cancers and arises from
thyroid C cells that produce calcitonin. Locally advanced or metastatic MTC requires a …

Until recently, patients with advanced thyroid cancers had limited options for systemic
treatment. With the introduction of tyrosine kinase inhibitors (TKIs) as a promising new class …

RET receptor tyrosine kinase acts as a mutated oncogenic driver in several human
malignancies and it is over-expressed in other cancers. Small molecule compounds with …

Phase I oncology trials are designed to identify a safe dose with an acceptable toxicity
profile. The dose is typically determined based on the probability of severe toxicity observed …

Although thyroid cancer usually has an excellent prognosis, few therapeutic options are
available in the refractory setting. Based on the recent results of phase II studies with …

Objective: In a phase III trial, Western patients with medullary thyroid cancer (MTC) treated
with the oral multikinase inhibitor vandetanib showed significantly improved progression …

ABSTRACT Introduction: Multi kinase inhibitors (MKIs) are new drugs, which show activity
against receptors of different growth factors leading to the inhibition of tumor cells growth …

Medullary thyroid carcinoma (MTC) is a hyperplasia of thyroid C-cells, accounting for 5–10%
of all thyroid cancers. MTCs may appear as sporadic or hereditary forms, and several …